Transplantation of human umbilical cord-derived mesenchymal stems cells for the treatment of Becker muscular dystrophy in affected pedigree members

Li,Pang; Cui,Kai; Zhang,Bo; Wang,Zhendan; Shen,Yangyang; Wang,Xiangyu; Zhang,Jianbo; Tong,Feng; Li,Sheng

doi:10.3892/ijmm.2015.2084

Transplantation of human umbilical cord-derived mesenchymal stems cells for the treatment of Becker muscular dystrophy in affected pedigree members

Authors:
- Pang Li
- Kai Cui
- Bo Zhang
- Zhendan Wang
- Yangyang Shen
- Xiangyu Wang
- Jianbo Zhang
- Feng Tong
- Sheng Li
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, Shandong Cancer Hospital, Jinan, Shandong 250011, P.R. China, Department of Pathology, Shandong Cancer Hospital, Jinan, Shandong 250011, P.R. China, The Dean's Office, Shandong Cancer Hospital, Jinan, Shandong 250011, P.R. China
Published online on: January 30, 2015 https://doi.org/10.3892/ijmm.2015.2084
Pages: 1051-1057

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The regeneration of muscle tissue has been achieved using multipotent mesenchymal stem cells in mouse models of injured skeletal muscle. In the present study, the utility of multipotent human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) in the treatment of Becker muscular dystrophy (BMD), a genetic disease where muscle tissue fails to regenerate, was examined in members from a pedigree affected by BMD. The disease status was evaluated in 4 affected pedigree members (II1, II2, II3 and III2; aged 50, 46, 42 and 6 years, respectively). The transplantation of the hUC‑MSCs (performed on 3 patients, I2, II3 and III2) was performed by infusion with an intravenous drip over a 30‑min period, and the patients were evaluated at 1, 3, 4 and 12 weeks following the procedure. The evaluation was based on physical characteristics, as well as on molecular testing for serum creatine kinase (CK) and lactate dehydrogenase (LDH) levels and a histological examination of muscle biopsies. The patients suffered no adverse reactions in response to the transplantation of the hUC‑MSCs. At 1 week following transplantation all 3 patients showed improvement in the muscle force of the limbs, muscle size and daily activity. The walking gait of patient III2 had improved by 1 week post-transplantation and reached a normal status by 12 weeks. Serum CK and LDH levels were decreased relative to the baseline levels. A histological examination of muscle biopsies displayed no obvious tissue regeneration. In conclusion, the treatment of patients with BMD using hUC-MSCs was safe and of therapeutic benefit that lasted for up to 12 weeks. hUC-MSCs are, therefore, a potential cell therapy-based treatment option for patients with muscular dystrophies.

View Figures

View References

1	Baskin B, Gibson WT and Ray PN: Duchenne muscular dystrophy caused by a complex rearrangement between intron 43 of the DMD gene and chromosome 4. Neuromuscul Disord. 21:178–182. 2011. View Article : Google Scholar
2	Winder SJ, Gibson TJ and Kendrick-Jones J: Dystrophin and utrophin: the missing links! FEBS Lett. 369:27–33. 1995. View Article : Google Scholar : PubMed/NCBI
3	Hoffman EP, Brown RH Jr and Kunkel LM: Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 51:919–928. 1987. View Article : Google Scholar : PubMed/NCBI
4	Koenig M, Monaco AP and Kunkel LM: The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell. 53:219–228. 1988. View Article : Google Scholar : PubMed/NCBI
5	Takeshima Y, Yagi M, Okizuka Y, et al: Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center. J Hum Genet. 55:379–388. 2010. View Article : Google Scholar : PubMed/NCBI
6	Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H and Kunkel LM: An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics. 2:90–95. 1988. View Article : Google Scholar : PubMed/NCBI
7	Hoffman EP, Fischbeck KH, Brown RH, et al: Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne’s or Becker’s muscular dystrophy. N Engl J Med. 318:1363–1368. 1988. View Article : Google Scholar : PubMed/NCBI
8	Finanger EL, Russman B, Forbes SC, Rooney WD, Walter GA and Vandenborne K: Use of skeletal muscle MRI in diagnosis and monitoring disease progression in Duchenne muscular dystrophy. Phys Med Rehabil Clin N Am. 23:1–10. 2012. View Article : Google Scholar : PubMed/NCBI
9	Sutherland DH, Olshen R, Cooper L, et al: The pathomechanics of gait in Duchenne muscular dystrophy. Dev Med Child Neurol. 23:3–22. 1981. View Article : Google Scholar : PubMed/NCBI
10	Rodino-Klapac LR, Mendell JR and Sahenk Z: Update on the treatment of Duchenne muscular dystrophy. Curr Neurol Neurosci Rep. 13:3322013. View Article : Google Scholar : PubMed/NCBI
11	Moxley RT III and Pandya S: Weekend high-dosage prednisone: a new option for treatment of Duchenne muscular dystrophy. Neurology. 77:416–417. 2011. View Article : Google Scholar : PubMed/NCBI
12	King WM, Ruttencutter R, Nagaraja HN, et al: Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology. 68:1607–1613. 2007. View Article : Google Scholar : PubMed/NCBI
13	Biggar WD, Harris VA, Eliasoph L and Alman B: Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord. 16:249–255. 2006. View Article : Google Scholar : PubMed/NCBI
14	Schram G, Fournier A, Leduc H, et al: All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy. J Am Coll Cardiol. 61:948–954. 2013. View Article : Google Scholar : PubMed/NCBI
15	Bushby K, Finkel R, Birnkrant DJ, et al: Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 9:77–93. 2010. View Article : Google Scholar
16	Baltgalvis KA, Call JA, Nikas JB and Lowe DA: Effects of prednisolone on skeletal muscle contractility in mdx mice. Muscle Nerve. 40:443–454. 2009. View Article : Google Scholar : PubMed/NCBI
17	Malik V, Rodino-Klapac LR and Mendell JR: Emerging drugs for Duchenne muscular dystrophy. Expert Opin Emerg Drugs. 17:261–277. 2012. View Article : Google Scholar : PubMed/NCBI
18	McElreavey KD, Irvine AI, Ennis KT and McLean WH: Isolation, culture and characterisation of fibroblast-like cells derived from the Wharton’s jelly portion of human umbilical cord. Biochem Soc Trans. 19:29S1991.
19	Wang HS, Hung SC, Pong ST, et al: Mesenchymal stem cells in the Wharton’s jelly of the human umbilical cord. Stem Cells. 22:1330–1337. 2004. View Article : Google Scholar
20	Fu YS, Shih YT, Cheng YC and Min MY: Transformation of human umbilical mesenchymal cells into neurons in vitro. J Biomed Sci. 11:652–660. 2004. View Article : Google Scholar : PubMed/NCBI
21	Lund RD, Wang S, Lu B, et al: Cells isolated from umbilical cord tissue rescue photoreceptors and visual functions in a rodent model of retinal disease. Stem Cells. 25:602–611. 2007. View Article : Google Scholar
22	Huang P, Lin LM, Wu XY, et al: Differentiation of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells into germ-like cells in vitro. J Cell Biochem. 109:747–754. 2010.PubMed/NCBI
23	Kadner A, Zund G, Maurus C, et al: Human umbilical cord cells for cardiovascular tissue engineering: a comparative study. Eur J Cardiothorac Surg. 25:635–641. 2004. View Article : Google Scholar : PubMed/NCBI
24	Li F, Li Y, Cui K, et al: Detection of pathogenic mutations and the mechanism of a rare chromosomal rearrangement in a Chinese family with Becker muscular dystrophy. Clin Chim Acta. 414:20–25. 2012. View Article : Google Scholar : PubMed/NCBI
25	Zhang Y, Huang JJ, Wang ZQ, Wang N and Wu ZY: Value of muscle enzyme measurement in evaluating different neuromuscular diseases. Clin Chim Acta. 413:520–524. 2012. View Article : Google Scholar
26	Vieira NM, Zucconi E, Bueno CR Jr, et al: Human multipotent mesenchymal stromal cells from distinct sources show different in vivo potential to differentiate into muscle cells when injected in dystrophic mice. Stem Cell Rev. 6:560–566. 2010. View Article : Google Scholar : PubMed/NCBI
27	Grabowska I, Brzoska E, Gawrysiak A, et al: Restricted myogenic potential of mesenchymal stromal cells isolated from umbilical cord. Cell Transplant. 21:1711–1726. 2012. View Article : Google Scholar : PubMed/NCBI
28	Ten Broek RW, Grefte S and Von den Hoff JW: Regulatory factors and cell populations involved in skeletal muscle regeneration. J Cell Physiol. 224:7–16. 2010.PubMed/NCBI
29	Kasemkijwattana C, Menetrey J, Somogyl G, et al: Development of approaches to improve the healing following muscle contusion. Cell Transplant. 7:585–598. 1998. View Article : Google Scholar : PubMed/NCBI
30	Menetrey J, Kasemkijwattana C, Day CS, et al: Growth factors improve muscle healing in vivo. J Bone Joint Surg Br. 82:131–137. 2000. View Article : Google Scholar : PubMed/NCBI
31	Deasy BM, Feduska JM, Payne TR, Li Y, Ambrosio F and Huard J: Effect of VEGF on the regenerative capacity of muscle stem cells in dystrophic skeletal muscle. Mol Ther. 17:1788–1798. 2009. View Article : Google Scholar : PubMed/NCBI
32	Izadpanah R, Trygg C, Patel B, et al: Biologic properties of mesenchymal stem cells derived from bone marrow and adipose tissue. J Cell Biochem. 99:1285–1297. 2006. View Article : Google Scholar : PubMed/NCBI
33	Prasanna SJ, Gopalakrishnan D, Shankar SR and Vasandan AB: Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS One. 5:e90162010. View Article : Google Scholar : PubMed/NCBI
34	Fong CY, Richards M, Manasi N, Biswas A and Bongso A: Comparative growth behaviour and characterization of stem cells from human Wharton’s jelly. Reprod Biomed Online. 15:708–718. 2007. View Article : Google Scholar : PubMed/NCBI
35	Capelli C, Gotti E, Morigi M, et al: Minimally manipulated whole human umbilical cord is a rich source of clinical-grade human mesenchymal stromal cells expanded in human platelet lysate. Cytotherapy. 13:786–801. 2011. View Article : Google Scholar : PubMed/NCBI
36	Romano G: Stem cell transplantation therapy: controversy over ethical issues and clinical relevance. Drug News Perspect. 17:637–645. 2004. View Article : Google Scholar
37	Lu LL, Liu YJ, Yang SG, et al: Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica. 91:1017–1026. 2006.PubMed/NCBI
38	Fong CY, Subramanian A, Biswas A, et al: Derivation efficiency, cell proliferation, freeze-thaw survival, stem-cell properties and differentiation of human Wharton’s jelly stem cells. Reprod Biomed Online. 21:391–401. 2010. View Article : Google Scholar : PubMed/NCBI